Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198591 | PMC |
| http://dx.doi.org/10.3389/fonc.2022.905654 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States-Author's Reply.
Aliment Pharmacol Ther
January 2025
Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, Arizona, USA.
Editorial Comment: LI-RADS Ultrasound Surveillance Version 2024 Results in Increased Sensitivity for Detecting Hepatocellular Carcinoma.
AJR Am J Roentgenol
January 2025
Department of Radiology, Penn State Health, Milton S Hershey Medical Center, 500 University Drive, Hershey, PA 17033.
Unraveling the therapeutic potential of Calculus Bovis in liver cancer: A novel step for targeted cancer treatment.
World J Gastroenterol
January 2025
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Hepatocellular carcinoma is one of the leading causes of cancer-related deaths globally, and effective treatments are urgently needed. The present study aimed to investigate the inhibitory effect of Calculus Bovis (CB) on liver cancer and the underlying mechanisms. CB inhibited M2 tumor-associated macrophage polarization and modulated the Wnt/β-catenin signaling pathway, thereby suppressing the proliferation of liver cancer cells.
View Article and Find Full Text PDFSystemic therapy for child-pugh B patients with hepatocellular carcinoma.
Expert Opin Emerg Drugs
January 2025
State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir YK Pao Centre for Cancer, The Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, China.
Structural insights into antibody-based immunotherapy for hepatocellular carcinoma.
Genomics Inform
January 2025
Department of Physiology, Ajou University School of Medicine, Suwon, 16499, Republic of Korea.
Hepatocellular carcinoma (HCC) is one of the most common types of primary liver cancer and remains a leading cause of cancer-related deaths worldwide. While traditional approaches like surgical resection and tyrosine kinase inhibitors struggle against the tumor's immune evasion, monoclonal antibody (mAb)-based immunotherapies have emerged as promising alternatives. Several therapeutic antibodies that counter the immunosuppressive tumor microenvironment have demonstrated efficacy in clinical trials, leading to FDA approvals for advanced HCC treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!